Alumis Inc. shares climbed 6.3% in pre-open trading after management laid out encouraging long-term results for envudeucitinib at the Cantor Fitzgerald Global Healthcare Conference on September 9. Executives described sustained skin-clearance outcomes in ongoing studies and said they are actively exploring partnership arrangements to extend the drug's commercial reach.
At the Cantor Fitzgerald event, company presenters emphasized the psoriasis program's durability, reporting that envudeucitinib achieved approximately 40% complete skin clearance at six months and roughly 55% at 48 weeks in ongoing trials. Management acknowledged that the lupus study produced mixed results and indicated a more focused pathway going forward, targeting a patient subgroup defined by a specific biomarker.
Investor perception of the news was bolstered by material insider buying earlier in September. Director Srinivas Akkaraju purchased more than 986,000 shares in the open market across two transactions on September 4 and September 8, with those acquisitions totaling in excess of $10.7 million. During the same short period he sold a smaller block of about 96,000 shares. The company notes these purchases as a noteworthy sign of insider conviction at current price levels.
Management reiterated at both the Wells Fargo Healthcare Conference on September 8 and the Cantor Fitzgerald session on September 9 that an ideal collaborator would be prepared to develop envudeucitinib across a broad range of indications on a global basis. Company executives framed such a partnership as having the potential to be transformative from a commercial standpoint.
Beyond corporate developments, broader market conditions were broadly neutral on the trading day in question. The S&P 500 inched up 0.1%, the Dow Jones Industrial Average rose 0.2%, and the NASDAQ slipped 0.1%. Those moves suggest that the advance in ALMS shares was largely driven by company-specific news rather than macroeconomic tailwinds.
Alumis also remains on schedule to file a New Drug Application with the U.S. Food and Drug Administration for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026, a near-term regulatory milestone the company and analysts point to as an important anchor for sentiment. Consensus analyst price targets are reported to be well above current trading levels.
Taken together, the favorable long-term psoriasis data highlighted at a high-profile investor conference, an explicit partnership strategy, and significant insider purchases combined to create a positive setup that lifted ALMS shares in pre-market trading. The move helped the stock regain some footing after earlier pressure related to the September 1 lupus trial disappointment.
Summary
Alumis rallied in pre-market trading after presenting long-term psoriasis results for envudeucitinib, signaling an active search for partners and seeing notable insider buying by a director. The company remains on track for an NDA submission in the fourth quarter of 2026 for plaque psoriasis.